| 摘要: |
| 当前,国内医药产业正逐渐登上国际舞台,澳大利亚作为国际药品认证合作组织(PIC/S)成员国之一,通过澳大利亚治疗用品管理局(TGA)的药品生产质量管理规范(GMP)认证,意味着获得了包括欧盟50多个国家在内的PICS成员国的药品准入。本文简要介绍了TGA的组织机构,生产许可流程,对比了国内药品生产许可与澳大利亚TGA生产许可流程的逻辑差异以及我国药品生产企业申请海外GMP认证的痛点与解决之道,以期帮助国内药品生产企业进行自身产业布局,简化澳大利亚 GMP 认证程序,顺利进入国际市场。 |
| 关键词: 澳大利亚 组织机构 生产许可 对比分析 |
| DOI:10.13506/j.cnki.jpr.2026.09.018 |
| 基金项目: |
|
收稿日期:2026-03-05
修回日期:2026-05-29
出版日期:2026-09-30
|
|
| Comparative analysis and application of pharmaceutical manufacturing licensing systems in Australia and China |
| ZHAO Jie,CHAI Fayong,SHI Yan,XING Xiaomin,FANG Juanjuan,CAO Hongyan |
| (Center for Evaluation and Certification,Shandong Food and Drug Administration,Jinan 250014,China) |
| Abstract: |
| At present, China's pharmaceutical industry is gradually gaining prominence on the international stage. As a member of PIC/S, obtaining GMP certification from Australia's TGA grants access to pharmaceutical markets in over 50 countries, including all PIC/S member states such as those in the EU. This article outlines the organizational structure of the Therapeutic Goods Administration (TGA) and its pharmaceutical manufacturing licensing procedures. It further compares the core logical differences between domestic pharmaceutical manufacturing licensing systems and Australia's TGA certification framework, identifies the pain points encountered by Chinese pharmaceutical enterprises during overseas Good Manufacturing Practice (GMP) certification applications, and proposes targeted solutions. The study aims to provide practical references for domestic pharmaceutical manufacturers to optimize their industrial layout, simplify the Australian GMP compliance process, and facilitate smooth access to the international pharmaceutical market. |
| Key words: Australia TGA structure Manufacturing licence Comparative analysis |